Prevalence, Characteristics, and One-Year Follow-Up of Congenital Cytomegalovirus Infection in Isfahan City, Iran.
Conclusions. The primary object of this study was determination of prevalence of cCMV infection in Iran as a developing country, which was at the lower range compared with other such countries. cCMV infection may result in short-term impairment in growth. PMID: 28070187 [PubMed - in process]
Conclusions: Symptomatic and asymptomatic congenital CMV infection should be considered a risk factor for hearing loss at birth and during childhood and for progressive hearing loss. Therefore, CMV should be included as a risk factor in screening and surveillance programs and be taken into account in clinical follow-up of children with hearing loss.
Conditions: Ocular Myasthenia Gravis; Cytomegalovirus Infections Intervention: Diagnostic Test: Serum acetylcholine receptor antibody, erythrocyte deposition rate, hypersensitive C protein, neostigmine test,thymus CT, low frequency repeated nerve stimulation Sponsor: XiaoYong Liu Recruiting
Behav Neurol. 2021 Oct 15;2021:9603660. doi: 10.1155/2021/9603660. eCollection 2021.ABSTRACTOBJECTIVE: To assess association between congenital cytomegalovirus (CMV) infection and brain injury in neonates.METHODS: The literatures from inception to November 4, 2020, were searched through PubMed, Embase, Cochrane Library, and Web of Science. Heterogeneity test was conducted for each indicator and measured by I 2 statistics. If I 2 ≥ 50%, the random effects model was applied; otherwise, the fixed effects model was used. Sensitivity analysis was performed for all models. Weighed mean difference (WMD) was used as the effect ...
Transmission of latent human cytomegalovirus (HCMV) via organ transplantation with post-transplant viral reactivation is extremely prevalent and results in substantial adverse impact on outcomes. Therapies targeting the latent reservoir within the allograft to mitigate viral transmission would represent a major advance. Here, we delivered an immunotoxin (F49A-FTP) that targets and kills latent HCMV aiming at reducing the HCMV reservoir from donor lungs using ex-vivo lung perfusion (EVLP).
Condition: Cytomegalovirus Infections Interventions: Biological: Pentamer (low)/gB(low)/Adjuvant vaccine; Biological: Pentamer (med)/gB(low)/Adjuvant vaccine; Biological: Pentamer (med)/gB(med)/Adjuvant vaccine; Biological: Pentamer (high)/gB(med)/Adjuvant vaccine; Drug: Placebo (saline) Sponsor: GlaxoSmithKline Not yet recruiting
CONCLUSION: We showed an association between the CMV infections occurrence and the trough lymphocyte level of CyA (CyA L0). Both lymphocyte CyA levels also correlated with the frequency of CMV infections. Further studies are needed to establish the optimal range of both CyA blood and lymphocyte levels and decrease the risk of opportunistic infections in high risk patients.PMID:34675757 | PMC:PMC8524715 | DOI:10.1177/15593258211042169
ram Brune Viral infection activates cellular antiviral defenses including programmed cell death (PCD). Many viruses, particularly those of the Herpesviridae family, encode cell death inhibitors that antagonize different forms of PCD. While some viral inhibitors are broadly active in cells of different species, others have species-specific functions, probably reflecting the co-evolution of the herpesviruses with their respective hosts. Human cytomegalovirus (HCMV) protein UL36 is a dual cell death pathway inhibitor. It blocks death receptor-dependent apoptosis by inhibiting caspase-8 activation, and necroptosis by bindi...
Clin Pharmacol Ther. 2021 Oct 21. doi: 10.1002/cpt.2456. Online ahead of print.ABSTRACTThe cytomegalovirus (CMV) viral terminase inhibitor letermovir is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive allogeneic hematopoietic stem cell transplantation (HSCT) recipients. In a phase 3 trial (NCT02137772), letermovir significantly reduced clinically significant CMV infection (CS-CMVi) rate versus placebo through week 24 (primary endpoint) and week 14 (secondary endpoint) post-transplantation. Here, exposure-response relationships were investigated using efficacy and selected safety endpoints fr...
Condition: Cytomegalovirus Infection Interventions: Biological: mRNA-1647; Biological: Placebo Sponsor: ModernaTX, Inc. Not yet recruiting